These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7332001)

  • 21. New insights about uremia through its attenuation by dialysis.
    Maher JF
    Artif Organs; 1986 Aug; 10(4):306-12. PubMed ID: 3753257
    [No Abstract]   [Full Text] [Related]  

  • 22. [On-line HFR and removal of uremic toxins inducing the loss of phospholipidic asymmetry of the erythrocyte membrane].
    Sirolli V; Cappelli P; Amoroso L; Di Liberato L; Muscianese P; Santarelli P; Del Rosso G; Bonomini M
    G Ital Nefrol; 2004; 21 Suppl 30():S208-11. PubMed ID: 15750987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical studies and chronic kidney disease: what did we learn recently?
    Liabeuf S; Neirynck N; Drüeke TB; Vanholder R; Massy ZA
    Semin Nephrol; 2014 Mar; 34(2):164-79. PubMed ID: 24780471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The anglerfish and uremic toxins.
    Lowenstein J
    FASEB J; 2011 Jun; 25(6):1781-5. PubMed ID: 21622695
    [No Abstract]   [Full Text] [Related]  

  • 26. Separation and characterization of uremic metabolites in biologic fluids: a screening approach to the definition of uremic toxins.
    Gordon A; Berström J; Fürst P; Zimmerman L
    Kidney Int Suppl; 1975 Jan; (2):45-51. PubMed ID: 1057692
    [No Abstract]   [Full Text] [Related]  

  • 27. Should dialysis modalities be designed to remove specific uremic toxins?
    Baurmeister U; Vienken J; Ward RA
    Semin Dial; 2009; 22(4):454-7. PubMed ID: 19709001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Uremic toxins: the case of protein-bound compounds].
    Basile C; Libutti P; Teutonico A; Lomonte C
    G Ital Nefrol; 2010; 27(5):498-507. PubMed ID: 20922681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal handling of uremic middle molecules. a study with the isolated perfused rat kidney.
    Schindhelm K; Schlatter E; Schurek HJ; Stolte H
    Nephron; 1982; 30(2):166-72. PubMed ID: 7099324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review on uremic toxins: classification, concentration, and interindividual variability.
    Vanholder R; De Smet R; Glorieux G; Argilés A; Baurmeister U; Brunet P; Clark W; Cohen G; De Deyn PP; Deppisch R; Descamps-Latscha B; Henle T; Jörres A; Lemke HD; Massy ZA; Passlick-Deetjen J; Rodriguez M; Stegmayr B; Stenvinkel P; Tetta C; Wanner C; Zidek W;
    Kidney Int; 2003 May; 63(5):1934-43. PubMed ID: 12675874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extracorporeal strategies for the removal of middle molecules.
    Winchester JF; Audia PF
    Semin Dial; 2006; 19(2):110-4. PubMed ID: 16551287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Membranes and their removal of uremic toxins.
    Hoenich NA
    Adv Exp Med Biol; 1987; 223():253-62. PubMed ID: 3447443
    [No Abstract]   [Full Text] [Related]  

  • 33. Advanced glycation endproducts (AGEs) as uremic toxins.
    Schwenger V; Zeier M; Henle T; Ritz E
    Nahrung; 2001 Jun; 45(3):172-6. PubMed ID: 11455783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Middle molecules as a marker of uremic toxins.
    Wu ZG; Liao LT; Cai ZH; Lu ZN; Cai YD; Sheng PF
    Adv Exp Med Biol; 1987; 223():33-7. PubMed ID: 3447449
    [No Abstract]   [Full Text] [Related]  

  • 35. [Uremic Toxins: how can we improve the removal today?].
    Teatini U; Romei Longhena G
    G Ital Nefrol; 2017 Sep; 34(5):89-101. PubMed ID: 28963830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The fraction b 4-2: isolation, characterization and biological activities with reference to uremic polyneuropathy.
    Man NK; Cueille G; Faguer P; Boudet J; Pierrat D; Zingraff J; Sausse A; Funck-Brentano JL
    Adv Exp Med Biol; 1987; 223():135-40. PubMed ID: 3447428
    [No Abstract]   [Full Text] [Related]  

  • 37. [Dialysis treatment of chronic kidney insufficiency in the uremic phase. Indications and limitations].
    Garini G; Savazzi G; Arisi L
    Recenti Prog Med; 1986 Sep; 77(9):440-3. PubMed ID: 3797795
    [No Abstract]   [Full Text] [Related]  

  • 38. New dialysis membrane for removal of middle molecule uremic toxins.
    Yamashita AC
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S217-9. PubMed ID: 11576959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein-bound uremic solutes: the forgotten toxins.
    Vanholder R; De Smet R; Lameire N
    Kidney Int Suppl; 2001 Feb; 78():S266-70. PubMed ID: 11169024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nervous system complications in uremia.
    Fraser CL; Arieff AI
    Ann Intern Med; 1988 Jul; 109(2):143-53. PubMed ID: 2837930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.